Georgiamune

Approach

Georgiamune partnered with Thermal to craft and execute a communications strategy that would elevate its scientific leadership and novel approach to immunotherapy. Together, we:

• • Refined Georgiamune’s narrative to highlight its first-in-class oral T-reg activator and its ability to modulate the immune system via the lymphatic route—avoiding systemic immune suppression.
  • Positioned founder and CEO Dr. Samir Khleif as a visionary leader translating decades of cancer immunology expertise into a new class of immune-reset therapies.
  • Amplified key milestones including clinical progress across multiple programs and the depth of the company’s pipeline, with messaging tailored to media, potential partners, and the investment community.
  • Built credibility with targeted storytelling that emphasized the scientific rigor behind the platform and its potential to transform how autoimmune and inflammatory diseases are treated.

Impact

Through our ongoing collaboration, Georgiamune has:

• • Increased awareness of its lymphatic-targeted immune-reset platform as a paradigm shift in immunology.
  • Attracted attention for its robust pipeline—three clinical-stage candidates in five years—and the potential to selectively restore immune balance without compromising protection against infections.
  • Positioned the Georgiamune team as bold innovators rethinking immune modulation, resulting in growing interest from potential partners, clinicians, and strategic investors.

Thermal continues to support Georgiamune with high-impact communications, ensuring that its pioneering work in reprogramming immune signaling is recognized as a transformative force in immunotherapy.